98 related articles for article (PubMed ID: 30375852)
1. "Methylene Bridge" to 5-HT
Abdelkhalek AS; Alley GS; Alwassil OI; Khatri S; Mosier PD; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2019 Mar; 10(3):1380-1389. PubMed ID: 30375852
[TBL] [Abstract][Full Text] [Related]
2. Superagonist, Full Agonist, Partial Agonist, and Antagonist Actions of Arylguanidines at 5-Hydroxytryptamine-3 (5-HT
Alix K; Khatri S; Mosier PD; Casterlow S; Yan D; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2016 Nov; 7(11):1565-1574. PubMed ID: 27533595
[TBL] [Abstract][Full Text] [Related]
3. The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors.
Lochner M; Thompson AJ
Neuropharmacology; 2016 Sep; 108():220-8. PubMed ID: 27108935
[TBL] [Abstract][Full Text] [Related]
4. Mapping the Orthosteric Binding Site of the Human 5-HT
Jack T; Leuenberger M; Ruepp MD; Vernekar SKV; Thompson AJ; Braga-Lagache S; Heller M; Lochner M
ACS Chem Neurosci; 2019 Jan; 10(1):438-450. PubMed ID: 30149702
[TBL] [Abstract][Full Text] [Related]
5. The binding of arylguanidines at 5-HT(3) serotonin receptors: a structure-affinity investigation.
Dukat M; Choi YN; Teitler M; Du Pre A; Herrick-Davis K; Smith C; Glennon RA
Bioorg Med Chem Lett; 2001 Jun; 11(12):1599-603. PubMed ID: 11412989
[TBL] [Abstract][Full Text] [Related]
6. Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: a QSAR study.
Glennon RA; Daoud MK; Dukat M; Teitler M; Herrick-Davis K; Purohit A; Syed H
Bioorg Med Chem; 2003 Oct; 11(20):4449-54. PubMed ID: 13129581
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron-5-HT
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
[TBL] [Abstract][Full Text] [Related]
8. Noncompetitive Inhibition of 5-HT3 Receptors by Citral, Linalool, and Eucalyptol Revealed by Nonlinear Mixed-Effects Modeling.
Jarvis GE; Barbosa R; Thompson AJ
J Pharmacol Exp Ther; 2016 Mar; 356(3):549-62. PubMed ID: 26669427
[TBL] [Abstract][Full Text] [Related]
9. Conformational Changes in the 5-HT
Munro L; Ladefoged LK; Padmanathan V; Andersen S; Schiøtt B; Kristensen AS
Mol Pharmacol; 2019 Dec; 96(6):720-734. PubMed ID: 31582575
[TBL] [Abstract][Full Text] [Related]
10. 2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
Dukat M; Alix K; Worsham J; Khatri S; Schulte MK
Bioorg Med Chem Lett; 2013 Nov; 23(21):5945-8. PubMed ID: 24035337
[TBL] [Abstract][Full Text] [Related]
11. The antimalarial drug proguanil is an antagonist at 5-HT3 receptors.
Lochner M; Thompson AJ
J Pharmacol Exp Ther; 2014 Dec; 351(3):674-84. PubMed ID: 25277140
[TBL] [Abstract][Full Text] [Related]
12. Mapping spatial relationships between residues in the ligand-binding domain of the 5-HT3 receptor using a molecular ruler.
Nyce HL; Stober ST; Abrams CF; White MM
Biophys J; 2010 May; 98(9):1847-55. PubMed ID: 20441748
[TBL] [Abstract][Full Text] [Related]
13. 5-HT(3) receptors.
Lummis SC
J Biol Chem; 2012 Nov; 287(48):40239-45. PubMed ID: 23038271
[TBL] [Abstract][Full Text] [Related]
14. Discriminating between 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Jun; 169(4):736-47. PubMed ID: 23489111
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of antidepressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists.
Mahesh R; Dhar AK; Jindal A; Bhatt S
Chem Biol Drug Des; 2014 May; 83(5):583-91. PubMed ID: 24330585
[TBL] [Abstract][Full Text] [Related]
16. The 5-HT3 receptor as a therapeutic target.
Thompson AJ; Lummis SC
Expert Opin Ther Targets; 2007 Apr; 11(4):527-40. PubMed ID: 17373882
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.
Kurzwelly D; Barann M; Kostanian A; Combrink S; Bönisch H; Göthert M; Brüss M
Pharmacogenetics; 2004 Mar; 14(3):165-72. PubMed ID: 15167704
[TBL] [Abstract][Full Text] [Related]
18. Menthol inhibits 5-HT3 receptor-mediated currents.
Ashoor A; Nordman JC; Veltri D; Yang KH; Shuba Y; Al Kury L; Sadek B; Howarth FC; Shehu A; Kabbani N; Oz M
J Pharmacol Exp Ther; 2013 Nov; 347(2):398-409. PubMed ID: 23965380
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P.
Emerit MB; Riad M; Fattaccini CM; Hamon M
J Neurochem; 1993 Jun; 60(6):2059-67. PubMed ID: 7684066
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in 5-HT3 receptor pharmacology.
Thompson AJ
Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
